ArticleFrontiers in endocrinology2026
Effects and interactive effects of high-altitude environment on metabolism in normal and diabetic populations: a comparative metabolomics study.
Article in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: High-altitude environments impose unique physiological stresses that may alter metabolic dysregulation in individuals with type 2 diabetes mellitus (T2DM). However, the key determinants driving altitude-specific metabolic differences in diabetic patients remain insufficiently characterized. This study aimed to identify critical metabolic biomarkers and pathways distinguishing T2DM patients residing at high versus low altitudes. Methods: Serum samples were collected from 100 participants stratified into four matched groups: high-altitude T2DM (H_T2DM), high-altitude healthy controls (H_HC), low-altitude T2DM (L_T2DM), and low-altitude healthy controls (L_HC). Metabolomic profiling was performed using ultra-performance liquid chromatography‒quadrupole time-of-flight mass spectrometry (UPLC‒Q‒TOF‒MS) to compare endogenous metabolite abundance across groups. Pathway topology analysis was conducted to annotate functional metabolic pathways, and multicenter validation was implemented to verify the robustness of candidate biomarkers. Results: A total of 26 differentially abundant endogenous metabolites were identified in H_T2DM patients relative to the other three groups, with 18 metabolites significantly upregulated and 8 downregulated. Pipecolic acid, lauric acid, guanosine, and kaempferol were identified as potential early biomarkers for high-altitude diabetes, collectively achieving a prediction accuracy of 92%. These biomarkers were linked to core metabolic pathways including lysine degradation, fatty acid biosynthesis, and purine metabolism. Multicenter validation further confirmed guanosine as the most robust and altitude-specific biomarker for T2DM. Discussion: Our comprehensive metabolomic analysis reveals distinct metabolic perturbations in T2DM patients under high-altitude conditions, highlighting guanosine as a unique biomarker for identifying altitude-related diabetic metabolic dysregulation. These findings advance our understanding of the pathophysiological mechanisms underlying T2DM in high-altitude environments and provide a potential diagnostic target for clinical management of diabetic populations in such regions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.